ACADIAN ASSET MANAGEMENT LLC

Position in CCCC — C4 Therapeutics, Inc.

CIK 916542 Boston, MA

Position in CCCC

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$8,434,949

+$3,461,846 QoQ

Shares Held

1,806,199

-4.5% QoQ

Ownership

1.47%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#19

of 147 holders

Holding Since

Jun 2023

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

ACADIAN ASSET MANAGEMENT LLC holds $731,256,203 across 167 Biotechnology names. CCCC ranks #20 (1.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	INCY	Incyte Corp	1,664,999	$188,744,286
2	REGN	Regeneron Pharmaceuticals, Inc.	157,440	$98,170,137
3	IMCR	Immunocore Holdings plc	1,209,894	$38,414,134
4	RIGL	Rigel Pharmaceuticals Inc	591,686	$23,146,756
5	EXEL	Exelixis, Inc.	421,444	$22,930,768
6	VRTX	Vertex Pharmaceuticals Inc / Ma	42,122	$20,923,261
7	TBPH	Theravance Biopharma, Inc.	1,174,910	$19,973,470
8	PRTA	Prothena Corp Public Ltd Co	2,010,645	$19,684,214

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$8,434,949	1,806,199	-4.5%	Shares	Defined	2026-08-13
2026-03-31	$4,973,103	1,890,914	+187.7%	Shares	Defined	2026-05-13
2025-12-31	$1,255,200	657,173	+413.0%	Shares	Defined	2026-02-10
2025-09-30	$284,399	128,108	-8.3%	Shares	Defined	2025-11-13
2025-06-30	$199,803	139,723	+404.9%	Shares	Defined	2025-08-07
2025-03-31	$44,280	27,675	-75.6%	Shares	Defined	2025-05-21
2024-06-30	$524,074	113,436	+415.8%	Shares	Defined	2024-08-06
2024-03-31	$179,682	21,993	-87.0%	Shares	Defined	2024-05-10
2023-12-31	$957,200	169,416	+504.8%	Shares	Defined	2024-02-13
2023-09-30	$52,106	28,014	-78.1%	Shares	Defined	2023-11-13
2023-06-30	$352,165	128,060	—	Shares	Defined	2023-08-07
No filing history on record for this holder in this stock.